Print
5 reasons to choose meltdose®
Choose the technology that makes sense for your patients and your business and is:
Clinically Proven
- The ability of MeltDose® technology to increase bioavailability and/or reduce food effect has been confirmed in numerous clinical studies with a range of poorly soluble compounds
- MeltDose® technology is the basis for partnerships between LCP and several leading international pharmaceutical companies
Commercially Viable
- The first MeltDose® based product, Fenoglide®, is approved by the FDA and marketed in the US
- Several MeltDose® based products are in late stage development and have already been manufactured on a commercial scale
- The MeltDose® manufacturing process has been inspected by the FDA and is fully validated in commercial scale
- The approval process is facilitated by the fact that MeltDose® uses exclusively GRAS excipients
Patent Protected
- MeltDose® basic patents do not expire until 2022
- MeltDose® is an efficient Life Cycle Management tool allowing patent life extension of marketed products
Scalable and Transferable
- MeltDose® employs conventional manufacturing equipment, does not require significant additional investment and is easily scalable to commercial batch sizes
- LCP can offer a custom made technology transfer program to allow you to manufacture your own MeltDose® based products
- MeltDose® manufacturing process has already been established at leading CMOs in both Europe and USA
Cost Effective and Flexible
- The cost of goods of the MeltDose® based tablets is comparable to that of conventional plain tablets
- MeltDose® can be used to create customized release profiles including immediate or controlled release and is suitable for enteric coating
- MeltDose® is a solvent-free, one-step process that can also be carried out in an inert atmosphere. The resulting granulate is suitable for direct compression to tablets